成人激情春色网,免费无遮挡无码永久在线观看视频

規(guī)格	庫(kù)存	目錄價(jià)	會(huì)員專享價(jià)	數(shù)量
5 mg	3-5days	￥450.00	登錄后可見(jiàn)	- +
10 mg	3-5days	￥650.00	登錄后可見(jiàn)	- +
25 mg	3-5days	￥950.00	登錄后可見(jiàn)	- +

規(guī)格

庫(kù)存

目錄價(jià)

會(huì)員專享價(jià)

數(shù)量

5 mg

3-5days

￥450.00

登錄后可見(jiàn)

- +

10 mg

3-5days

￥650.00

登錄后可見(jiàn)

- +

25 mg

3-5days

￥950.00

登錄后可見(jiàn)

- +

基本信息

英文名稱	Quizartinib (AC220)
中文名稱	奎扎替尼
CAS號(hào)	950769-58-1
分子式	C29H32N6O4S
分子量	560.67
外觀	White to off-white powder
儲(chǔ)存條件	Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years).

產(chǎn)品詳情

Quizartinib (formerly also know as AC-220; AC-010220, Vanflyta) is a novel, potent, 2nd-generation, and orally bioavailable FLT3 tyrosine kinase inhibitor for Flt3 (ITD/WT) with potential anticancer activity.With IC50s of 1.1 nM and 4.2 nM, respectively, it inhibits FLT3 in MV4-11 and RS4EL11 cells. With respect to KIT, PDGFRα, PDGFRβ, RET, and CSF-1R, it demonstrates a ten-fold greater selectivity. Currently, Daiichi Sankyo is developing quizartinib to treat acute myeloid leukemia. Quizartinib (Vanflyta) was approved in 2023 by FDA for treating AML.

相關(guān)文獻(xiàn)

抱歉，暫時(shí)沒(méi)有相關(guān)文獻(xiàn)

相關(guān)產(chǎn)品

抱歉，暫時(shí)沒(méi)有相關(guān)產(chǎn)品

瀏覽記錄

CL2519

奎扎替尼

950769-58-1 98+% 3-5days

￥450.00 5 mg

欧美日韩成人一区二区三区,成人污污污WWW网站免费直播,久久综久久美利坚合众国,国产精品人妻一区二区三区四区

奎扎替尼

Quizartinib (AC220)

化學(xué)品安全說(shuō)明書(shū)(MSDS)